Li Liang (Lillian) has over 20 years of China regulatory experience at GSK, Sanofi, Fournier (acquired by Solvay/Abbott), and Takeda. Her regulatory and registration experience spans multiple therapeutic areas, having spearheaded import and local manufacturing initiatives in support of multi-regional clinical trials. Li was the key regulatory expert for over 20 INDs and 10 NDA approvals/launches. As a leading practitioner in China’s rapidly developing regulatory landscape, Li has played a key role in supporting global business development for multi-national organizations.
Li received her Bachelor’s degree in Pharmacy from School of Pharmacy, Lanzhou University (formerly Lanzhou Medical College).